Droplet Digital PCR Based Androgen Receptor Variant 7 (AR-V7) Detection from Prostate Cancer Patient Blood Biopsies

International Journal of Molecular Sciences

Therese M. Becker¹  Bavanthi Balakrishnar¹  Alison Luk²  David Lynch²  Yafeng Ma²  Francis P. Young²  Paul de Souza³  Wei Chua³ 

[1] Goulburn St., Liverpool, NSW 2170, Australia;Centre for Circulating Tumor Cell Diagnostics and Research, Ingham Institute for Applied Medical Research, 1 Campbell St., Liverpool, NSW 2170, Australia;;Department of Medical Oncology, Liverpool Hospital, Elizabeth St &

关键词: biomarker;    androgen receptor;    AR-V7;    prostate cancer;    ddPCR;    CTC;   

DOI  :  10.3390/ijms17081264

来源: DOAJ

【 摘 要 】

Androgen receptor splice variant V7 (AR-V7) was recently identified as a valuable predictive biomarker in metastatic castrate-resistant prostate cancer. Here, we report a new, sensitive and accurate screen for AR-V7 mRNA expression directly from circulating tumor cells (CTCs): We combined EpCAM-based immunomagnetic CTC isolation using the IsoFlux microfluidic platform with droplet digital polymerase chain reaction (ddPCR) to analyze total AR and AR-V7 expression from prostate cancer patients CTCs. We demonstrate that AR-V7 is reliably detectable in enriched CTC samples with as little as five CTCs, even considering tumor heterogeneity, and confirm detection of AR-V7 in CTC samples from advanced prostate cancer (PCa) patients with AR-V7 detection limited to castrate resistant disease status in our sample set. Sensitive molecular analyses of circulating tumor cells (CTCs) or circulating tumor nucleic acids present exciting strategies to detect biomarkers, such as AR-V7 from non-invasive blood samples, so-called blood biopsies.

【 授权许可】

Unknown